Advanced solid tumor/s, Ovarian, breast, prostate, and pancreatic cancers
EIKNEikon TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for EIK1003 in Advanced solid tumor/s, Ovarian, breast, prostate, and pancreatic cancers. The expected timing is based on the latest available company guidance and may change.
05/30/26:- EIK1003 Ph1/2 updated monotherapy and paclitaxel combo data presented at ASCO 2026; Ph2 dose optimization trial initiated. 07/20/26:- ESMO 2026 to present updated Ph1/2 monotherapy and paclitaxel-cohort data. 08/13/26:- EIK1003 updated Cohorts 1A and 1C and initial Cohort 1B data will be presented October 23, 2026. Cohort 1D enrollment continues.
Verification
Confirm timing and program details against the company announcement or filing.